Association between Common Genetic Polymorphisms in 1,994 Cancer-related Genes and Survival of Early-stage Non-small Cell Lung Cancer
분야
의약학 > 내과학
저자
유승수 , ( Yi Young Cho ) , ( Hyo Sung Jeon ) , ( Shin Yup Lee ) , ( Yang Ki Seok ) , ( Jae Hee Lee ) , ( Seung Ick Cha ) , ( Chang Ho Kim ) , ( Eung Bae Lee ) , ( Young Tae Kim ) , ( Sang Hoon Jheon ) , ( Jae Yong Park )
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 173(총1페이지)
파일형식
0y909854.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Purpose: This study was conducted to identify genetic polymorphisms associated with the prognosis of patients with early-stage non-small cell lung cancer (NSCLC). Materials and Methods: We genotyped 2,228 potentially functional single nucleotide polymorphisms (SNPs) of 1,994 genes using the Affymetrix custom-made GeneChip, which were related to the development and progression of cancer, in 166 NSCLC patients who underwent curative surgical resection. A replication study was performed on an independent cohort of 626 patients. The functional effect of GNB2L1 SNPs was evaluated by promoter assay and electrophoretic mobility shift assay (EMSA). Results: Among 2,228 SNPs, 13 SNPs which were associated with overall survival (OS) and/or disease-free survival (DFS) with log-rank P values lower than 0.10 in a discovery set were selected for validation. Among the 13 validation SNPs, 5 SNPs (C3 rs2287845, GNB2L1 rs1279736 and rs3756585, FANCD2 rs7647987, and SCGB1D2 rs2232950) were found to be associated with survival outcomes in the same direction as the discovery set. In combined analysis, the rs1279736 and rs3756585 were most significantly associated with OS and DFS in multivariate analysis (p for OS<0.0001, both; and P for DFS=0.003, both; under a codominant model). The promoter assay and EMSA revealed that the rs3795685 lead to change of promoter activity and binding of transcription factors. Conclusions: We identified five SNPs as markers for prognosis of patients with surgically resected NSCLC.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.